| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 29, 2025 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 11,000 | $316.07 | $3,476,765.35 | -4.3% | -4.7% | +73.8% | |
| May 28, 2025 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 11,581 | $52.98 | $613,537.06 | -22.8% | -15.0% | -52.4% | |
| May 28, 2025 | GTBIF Green Thumb Industries Inc. | Rslgh, LLC | 10% Owner | Buy | 32,300 | $25.20 | $813,869.00 | +1.6% | - | - | |
| May 28, 2025 | LFCR Lifecore Biomedical, Inc. \de\ | English Aron R.50 | 10% Owner | Sell | 1,386,060 | $6.59 | $9,132,503.00 | -38.3% | +8.7% | -28.0% | |
| May 28, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Patel Sanj K | Chairman &CEO | Sell | 86,270 | $27.24 | $2,349,981.45 | -22.9% | +23.1% | +86.5% | |
| May 27, 2025 | LLY Eli Lilly & Co | Zakrowski Donald A | SVP, Finance, &CAO | Sell | 1,000 | $716.41 | $716,410.00 | -17.1% | -4.1% | +49.3% | |
| May 27, 2025 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 3,233 | $55.87 | $180,627.71 | -2.1% | -19.4% | -52.8% | |
| May 27, 2025 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles56 | Director | Sell | 9,613 | $120.38 | $1,157,211.02 | -1.8% | +9.3% | +27.1% | |
| May 27, 2025 | VREOF Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% Owner | Buy | 64,000 | $0.38 | $24,512.80 | - | - | - | |
| May 23, 2025 | EBS Emergent Biosolutions Inc. | Katkin Keith65 | Director | Sell | 7,844 | $6.30 | $49,417.20 | -8.3% | +45.6% | +32.0% | |
| May 22, 2025 | HIMS Hims & Hers Health, Inc. | Becklund Irene | Pao | Sell | 5,071 | $53.51 | $271,349.21 | -100% | -18.9% | -55.6% | |
| May 22, 2025 | INIS International Isotopes Inc | Bagerdjian Shahe | Pres. &CEO | Buy | 140,000 | $0.05 | $7,000.00 | +1.6% | - | - | |
| May 20, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Patel Sanj K | Chairman &CEO | Sell | 2,349 | $27.02 | $63,469.98 | -2.4% | +26.3% | +103.3% | |
| May 20, 2025 | MDCX Medicus Pharma Ltd. | Velocity Fund Partners, LP | 10% Owner | Sell | 75,000 | $7.72 | $578,940.00 | -2.3% | -73.7% | -96.2% | |
| May 19, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Tessari Eben | Chief Operating Officer | Sell | 12,000 | $26.41 | $316,920.00 | -14.2% | +26.1% | +99.5% | |
| May 16, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Shah Nikita53 | Executive Vice President | Sell | 49,140 | $7.58 | $372,481.20 | -11.2% | +23.6% | +57.0% | |
| May 16, 2025 | IRWD Ironwood Pharmaceuticals Inc | Gaskins Tammi L | Chief Commercial Officer | Sell | 2,563 | $0.58 | $1,486.54 | -1.0% | +87.7% | +528.1% | |
| May 16, 2025 | IRWD Ironwood Pharmaceuticals Inc | McCourt Thomas A66 | Chief Executive Officer | Sell | 13,353 | $0.58 | $7,744.74 | -1.2% | +87.7% | +528.1% | |
| May 16, 2025 | HIMS Hims & Hers Health, Inc. | Dudum Andrew47 | Chief Executive Officer | Sell | 175,661 | $58.36 | $10,251,387.69 | -13.7% | -27.1% | -61.3% | |
| May 15, 2025 | ANIP Ani Pharmaceuticals Inc | Gutwerg Ori47 | SVP, Generics | Sell | 881 | $60.07 | $52,921.67 | -1.0% | +49.1% | +31.0% | |
| May 15, 2025 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 11,581 | $60.22 | $697,462.25 | -9.2% | -17.5% | -57.2% | |
| May 15, 2025 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 11,000 | $295.10 | $3,246,149.92 | -3.4% | +1.9% | +87.1% | |
| May 15, 2025 | ORGO Organogenesis Holdings Inc. | Nussdorf Glenn H70 | Director, 10% Owner | Buy | 358,495 | $3.06 | $1,096,039.47 | +142.8% | +62.0% | - | |
| May 14, 2025 | OGN Organon & Co. | Cox Carrie Smith51 | Director | Buy | 12,469 | $8.07 | $100,591.16 | New | +12.6% | - | |
| May 14, 2025 | LLY Eli Lilly & Co | Yuffa Ilya | EVP &President, Lly Int'l | Sell | 1,250 | $749.24 | $936,550.00 | -4.3% | -10.6% | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.